Marie Herr1,2, Nicolas Sirven3,4, Hélène Grondin5, Sylvain Pichetti3, Catherine Sermet3. 1. UMR 1168, Vieillissement et Maladies Chroniques : Approches Epidémiologique et de Santé Publique, INSERM and Université Versailles St-Quentin-en-Yvelines, Villejuif & Montigny-le-Bretonneux, France. marie.herr@uvsq.fr. 2. Département Hospitalier d'Epidémiologie et de Santé Publique, Hôpital Sainte-Périne, Assistance Publique-Hôpitaux de Paris, Paris, France. marie.herr@uvsq.fr. 3. Institut de Recherche et Documentation en Economie de la Santé (IRDES), Paris, France. 4. LIRAES, Université Paris Descartes, Paris, France. 5. UMR 1168, Vieillissement et Maladies Chroniques : Approches Epidémiologique et de Santé Publique, INSERM and Université Versailles St-Quentin-en-Yvelines, Villejuif & Montigny-le-Bretonneux, France.
Abstract
PURPOSE: This study analyses the relationship between medication use and frailty by considering the quantity of medications prescribed (polypharmacy) and the quality of medication prescribing (according to French criteria for Potentially Inappropriate Medications-PIMs) in people aged 65 and over. METHODS: This is a cross-sectional study based on the data from a nationally representative study about health and use of healthcare resources in France (ESPS 2012). The number of frailty criteria was assessed among exhaustion, unintentional weight loss, muscle weakness, impaired mobility, and low level of physical activity. Polypharmacy and PIMs were assessed from the data of reimbursement by the National Health Insurance over the whole year 2012. PIMs were defined according to the Laroche list plus additional criteria dealing with inappropriate prolonged use of medications. The analyses used Poisson regression models, with the number of frailty criteria as dependent variable. RESULTS: The study population was composed of 1003 women and 887 men, of mean age 74.7 +/- 7.4 years. Polypharmacy (5 to 9 drugs) and excessive polypharmacy (≥10 drugs) were reported in 42.9 and 27.4% of the study population, respectively, while 46.7% of the study population received at least one PIM during the year 2012. Polypharmacy and PIMs were both associated with the number of frailty criteria in models adjusted for socio-demographic and health characteristics of the participants. The prescription of anticholinergic medications was the only PIM that remained significantly associated with the number of frailty criteria after adjustment for polypharmacy. CONCLUSIONS: Polypharmacy and use of anticholinergic medications are independently associated with frailty in old people.
PURPOSE: This study analyses the relationship between medication use and frailty by considering the quantity of medications prescribed (polypharmacy) and the quality of medication prescribing (according to French criteria for Potentially Inappropriate Medications-PIMs) in people aged 65 and over. METHODS: This is a cross-sectional study based on the data from a nationally representative study about health and use of healthcare resources in France (ESPS 2012). The number of frailty criteria was assessed among exhaustion, unintentional weight loss, muscle weakness, impaired mobility, and low level of physical activity. Polypharmacy and PIMs were assessed from the data of reimbursement by the National Health Insurance over the whole year 2012. PIMs were defined according to the Laroche list plus additional criteria dealing with inappropriate prolonged use of medications. The analyses used Poisson regression models, with the number of frailty criteria as dependent variable. RESULTS: The study population was composed of 1003 women and 887 men, of mean age 74.7 +/- 7.4 years. Polypharmacy (5 to 9 drugs) and excessive polypharmacy (≥10 drugs) were reported in 42.9 and 27.4% of the study population, respectively, while 46.7% of the study population received at least one PIM during the year 2012. Polypharmacy and PIMs were both associated with the number of frailty criteria in models adjusted for socio-demographic and health characteristics of the participants. The prescription of anticholinergic medications was the only PIM that remained significantly associated with the number of frailty criteria after adjustment for polypharmacy. CONCLUSIONS: Polypharmacy and use of anticholinergic medications are independently associated with frailty in old people.
Authors: Howard Bergman; Luigi Ferrucci; Jack Guralnik; David B Hogan; Silvia Hummel; Sathya Karunananthan; Christina Wolfson Journal: J Gerontol A Biol Sci Med Sci Date: 2007-07 Impact factor: 6.053
Authors: Danijela Gnjidic; Sarah N Hilmer; Fiona M Blyth; Vasi Naganathan; Louise Waite; Markus J Seibel; Andrew J McLachlan; Robert G Cumming; David J Handelsman; David G Le Couteur Journal: J Clin Epidemiol Date: 2012-06-27 Impact factor: 6.437
Authors: D Gnjidic; S N Hilmer; F M Blyth; V Naganathan; R G Cumming; D J Handelsman; A J McLachlan; D R Abernethy; E Banks; D G Le Couteur Journal: Clin Pharmacol Ther Date: 2012-02-01 Impact factor: 6.875
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: M Jardin; A Bocquier; S Cortaredona; S Nauleau; C Millon; S Savard-Chambard; V Allaria-Lapierre; V Sciortino; G Bouvenot; P Verger Journal: Rev Epidemiol Sante Publique Date: 2012-03-13 Impact factor: 1.019
Authors: Kai-Uwe Saum; Ben Schöttker; Andreas D Meid; Bernd Holleczek; Walter E Haefeli; Klaus Hauer; Hermann Brenner Journal: J Am Geriatr Soc Date: 2016-12-26 Impact factor: 5.562
Authors: Terri R Fried; John O'Leary; Virginia Towle; Mary K Goldstein; Mark Trentalange; Deanna K Martin Journal: J Am Geriatr Soc Date: 2014-12 Impact factor: 5.562
Authors: John E Morley; Bruno Vellas; G Abellan van Kan; Stefan D Anker; Juergen M Bauer; Roberto Bernabei; Matteo Cesari; W C Chumlea; Wolfram Doehner; Jonathan Evans; Linda P Fried; Jack M Guralnik; Paul R Katz; Theodore K Malmstrom; Roger J McCarter; Luis M Gutierrez Robledo; Ken Rockwood; Stephan von Haehling; Maurits F Vandewoude; Jeremy Walston Journal: J Am Med Dir Assoc Date: 2013-06 Impact factor: 4.669
Authors: M Gutiérrez-Valencia; M Izquierdo; M Cesari; Á Casas-Herrero; M Inzitari; N Martínez-Velilla Journal: Br J Clin Pharmacol Date: 2018-05-03 Impact factor: 4.335
Authors: Monika P Oktora; Petra Denig; Jens H J Bos; Catharina C M Schuiling-Veninga; Eelko Hak Journal: PLoS One Date: 2019-03-22 Impact factor: 3.240
Authors: Rodrigo Pérez-Rodríguez; Tania Guevara-Guevara; Pedro A Moreno-Sánchez; Elena Villalba-Mora; Myriam Valdés-Aragonés; Myriam Oviedo-Briones; José A Carnicero; Leocadio Rodríguez-Mañas Journal: Front Endocrinol (Lausanne) Date: 2020-05-13 Impact factor: 5.555
Authors: Dana Clarissa Muhlack; Liesa Katharina Hoppe; Kai-Uwe Saum; Walter E Haefeli; Hermann Brenner; Ben Schöttker Journal: Age Ageing Date: 2019-12-01 Impact factor: 10.668
Authors: Annette Eidam; Anja Roth; André Lacroix; Sabine Goisser; Hanna M Seidling; Walter E Haefeli; Jürgen M Bauer Journal: Patient Prefer Adherence Date: 2020-03-04 Impact factor: 2.711